CD274 and neoplasm: However, only a part of the tumor patients with PD-L1 expression showed a clinical response, while other patients (without PD-L1 staining) showed clinical benefit, indicating that there may be other factors in the tumor microenvironment (such as the expression of PD-L1 in stromal cell), which affected the benefits patients.